← Back to headlines
Supernus outlines $840M–$870M 2026 revenue target as ONAPGO supply normalizes and growth brands accelerate
Supernus Pharmaceuticals has outlined its revenue target for 2026, expecting $840M–$870M, driven by normalized ONAPGO supply and growth brands.
25 Feb, 09:28 — 25 Feb, 09:28
ℹOnly 1 source covers this story
